- Home
- CABA vs VEEA Comparison
CABA vs VEEA Comparison
Compare CABA & VEEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- VEEA
- Stock Information
- Founded
- CABA 2017
- VEEA 2014
- Country
- CABA United States
- VEEA United States
- Employees
- CABA N/A
- VEEA N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- VEEA
- Sector
- CABA Health Care
- VEEA
- Exchange
- CABA Nasdaq
- VEEA NYSE
- Market Cap
- CABA 118.8M
- VEEA 112.2M
- IPO Year
- CABA 2019
- VEEA N/A
- Fundamental
- Price
- CABA $1.55
- VEEA $1.56
- Analyst Decision
- CABA Strong Buy
- VEEA
- Analyst Count
- CABA 8
- VEEA 0
- Target Price
- CABA $26.13
- VEEA N/A
- AVG Volume (30 Days)
- CABA 801.5K
- VEEA 22.7K
- Earning Date
- CABA 05-14-2025
- VEEA 05-23-2025
- Dividend Yield
- CABA N/A
- VEEA N/A
- EPS Growth
- CABA N/A
- VEEA N/A
- EPS
- CABA N/A
- VEEA N/A
- Revenue
- CABA N/A
- VEEA $140,035.00
- Revenue This Year
- CABA $101.54
- VEEA N/A
- Revenue Next Year
- CABA N/A
- VEEA N/A
- P/E Ratio
- CABA N/A
- VEEA N/A
- Revenue Growth
- CABA N/A
- VEEA N/A
- 52 Week Low
- CABA $1.45
- VEEA $1.33
- 52 Week High
- CABA $19.04
- VEEA $18.56
- Technical
- Relative Strength Index (RSI)
- CABA 34.36
- VEEA N/A
- Support Level
- CABA $1.45
- VEEA N/A
- Resistance Level
- CABA $1.85
- VEEA N/A
- Average True Range (ATR)
- CABA 0.14
- VEEA 0.00
- MACD
- CABA -0.00
- VEEA 0.00
- Stochastic Oscillator
- CABA 17.86
- VEEA 0.00
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
About VEEA VEEA INC
Veea Inc is a company providing edge platform having extensive knowledge and expertise on content delivery and edge computing, and has brought a broad range of Wi-Fi, 4G/5G mobile wireless, and IoT products to market over the past two decades. It has first-in-class VeeaHub smart computing hubs integrate a full range of connectivity options, application processing power, and a full security stack to form an elastic edge computing platform with a dynamic connectivity and application mesh that can easily be deployed and centrally managed from the cloud.